listed for transplant experienced delays in navigating the evaluation process. 9 Unfortunately, waitlisting alone does not guarantee transplant access for HIV+ patients. A recent analysis of waitlist outcomes among HIV+ transplant candidates demonstrated that they were 13% less likely to receive a deceased donor kidney transplant, compared to HIV-candidates. 10 This disparate access to transplantation is particularly concerning given that HIV+ transplant candidates are predominantly young and African American. 10 The reasons for this disparity are unknown.
Transplantation is a highly regulated field, with patient and allograft outcomes reported publicly, 11 and these ratings are used to make decisions regarding insurance reimbursements as well as the ability to operate a transplant program. 12 Regulatory oversight is important for ensuring high-quality care but can have unintended consequences, namely restricting access to transplantation for candidates deemed to be high risk or encouraging the discard of donor organs likely to have poor function. The impact of transplant center performance evaluations on transplant volumes and candidate selection has been clearly demonstrated; centers that have been rated as "low performing" are more likely to delist candidates 13, 14 and less likely to utilize lower-quality organs. 15 We hypothesized that organs are more likely to be declined on behalf of HIV+ candidates, resulting in a lower transplant rate.
In order to examine whether organ refusals negatively impact access to transplantation for HIV+ candidates on the waitlist, we performed a novel data linkage between OPTN match run data and a detailed dataset from a national dialysis provider for ascertainment of HIV and HCV serostatus at the time of waitlisting. We compared time to first organ offer and the total number of organ offers made to HIV+ or HIV/HCV co-infected candidates to those received by patients with HCV infection (HCV+, another high-risk group) and HIV-/HCV-patients. Due to the fact that HIV and HCV information is not reported among waitlisted patients in the transplant registry, we used this unique linked dataset to generate novel insights into patterns of organ acceptance and transplantation according to the viral serostatus of waitlisted patients.
| PATIENTS AND ME THODS

| Data sources
This study used data from the Organ Procurement and Transplantation Network (OPTN). The OPTN database includes data on all donor, waitlisted candidates, and transplant recipients in the As HIV and HCV serostatus are not collected by the OPTN at the time of waitlist registration, serostatus information was obtained by merging the OPTN match run data with contemporary clinical data from a large dialysis provider (DaVita) with >2800 dialysis facilities in 47 states.
| Subjects
Kidney transplant candidates were included if they were waitlisted between May 1, 2007, to July 3, 2013 (dates of the available match run data), were ≥18 years of age and had viral serostatus information available from the dialysis provider. Please see the Appendix S1 for additional details regarding cohort selection.
| Primary exposure
The primary exposures were HIV and HCV serostatus. HCV and HIV serostatus were obtained from dialysis provider data. HCV serostatus was determined by routine dialysis unit screening with HCV antibody testing. Results were reported as "positive," "negative," or "indeterminate"; only individuals with a positive or negative result were included. HIV status was determined using International
Classification of Diseases-9 (ICD-9) codes indicative of HIV infection (042.0, V08, 079.53, and 795.71) 16 and/or by a home medication list including HIV-specific antiretroviral medications (ART). 17 Patients prescribed emtricitabine, lamivudine, or tenofovir without additional ART were not included in the HIV+ group as these medications can be used to treat hepatitis B virus (HBV) infection.
| Outcomes and covariates
For the multivariable analyses, the primary outcomes were time to . Please see Appendix S1 for a detailed description of covariates.
| Statistical analyses
Statistical analyses were performed with STATA version 15.0 for additional details regarding the statistical analyses. 
| RE SULTS
| Candidate characteristics
| Donor characteristics
During the study period, there were a total of 327 054 kidney organ offers among candidates and donors who met inclusion criteria. The median KDPI of all the offers was 57% (interquartile range [IQR] 33-79%) and 8060 kidneys were accepted for transplantation. When stratified by candidate serostatus, the median KDPI of all offers made during the time period did not differ clinically ( candidates. HIV-/HCV-candidates were significantly more likely to ultimately accept a live donor kidney (18%) compared to HCV+ (7%), HIV+ (12%), and HIV+/HCV+ (3%) candidates (P < 0.001).
| Organ offer characteristics
Among those individuals who received organ offers, the median number of offers a candidate received differed across serostatus groups ( 
| Cox proportional hazards models
In multivariable models ( Figure 2 , In multivariable models constructed for the outcome of time to kidney transplantation from the first offer ( Figure 3 , Table S2 ), HCV was associated with a higher probability of transplantation (aHR CI: 0.58-0.99). In models that accounted for death as a competing risk ( Figure S1 , Table S3 ), there was no significant difference in time to transplantation by serostatus. In models that censored for live donor kidney transplantation ( Figure S2 , Table S4 ), HCV+ candidates continued to have a higher rate of transplantation, but there was no significant difference for HIV+ candidates or HIV+/HCV+ candidates.
| D ISCUSS I ON
Here, we present the first analysis of OPTN match run data assessing differences in organ offers on the basis of HCV and HIV serostatus. We found that while the quality of the organs accepted for transplantation across serostatus groups, as measured by KDPI, was similar, patients with HIV or HIV/HCV co-infection received fewer organ offers overall and later in the match run sequence. This translated into a 12% lower likelihood of receiving a first organ offer for HIV+ candidates, and 18% lower likelihood of transplantation after the first offer for HIV+ recipients in the adjusted analyses.
HIV+ candidates face numerous barriers to transplantation. They are subject to a more intensive evaluation process that often prolongs their time to waitlisting. 9 Not all transplant centers will accept them as candidates, although the number of transplants performed in HIV+ recipients at centers that did not participate in the original NIH multicenter trial has grown. 18 There may be barriers at the When HIV+ candidates were compared to another "high-risk"
group, HCV+ candidates, we still observed significant differences in access to organ offers. When we excluded offers from HCV+ donors, there was still a shorter time to first offer for these patients, but the magnitude of their advantage was diminished, indicating that not all of their wait-time brevity comes from access to HCV+ organs. This is consistent with the survey results reported by Halpern et al where HCV+ candidates were viewed as "more appropriate" for transplantation than those with HIV. 20 As our study was conducted with data from the pre-direct-acting antiviral (DAA) era, we would expect these differences to be magnified, with HCV+ candidates having better access now that there are effective therapies for HCV that can be safely used in the post-transplant setting; HIV/HCV co-infected candidates might also be perceived as lower risk now that their HCV is curable and have improved access. This remains to be proven.
It is not surprising that the majority of organs offered to HIV+ and HIV/HCV+ candidates met PHS increased risk criteria; however, Our study has a number of strengths. It is the first of its kind to examine the impact of serostatus on organ acceptance or refusals due to a novel linkage with dialysis data that enabled us to identify HIV+ patients on the waiting list. These data provide important insights that help explain in part the observed disparity in deceased donor transplantation rates for HIV+ patients. Our models were clustered on transplant center to account for center-level practice differences.
There are limitations to our study. We had insufficient power to comment extensively upon HIV+/HCV+ candidates due to the small number of patients in the co-infected group. We were limited by use of HCV antibody testing to identify patients with HCV (or HIV/HCV) infection, and no viral load data were available.
Therefore, we cannot identify patients who have spontaneously cleared their HCV infection or been treated successfully with interferon. However, given that interferon is not very effective at curing HCV (summary sustained viral response rate 33%) 25 may not yet be apparent.
Patients with HIV still encounter barriers to transplantation, even after being placed on the transplant waiting list. Further study to elucidate the reasons why they are not offered organs while actively listed will be an important step toward improving access to transplantation in this vulnerable population.
F I G U R E 3 Cox proportional hazards models for time to transplantation. The figure demonstrates hazard ratios and 95% confidence intervals relative to the reference group (uninfected patients).
All adjusted analyses are adjusted for candidate age, race, diabetes status, dialysis vintage, maximum panel reactive antibody, and kidney donor profile index; all analyses use robust sandwich estimation to address dependence between observations within any given listing center
